Endotoxin induces downregulation of tumor necrosis factor receptors on circulating monocytes and granulocytes in humans.

Leukocytes rapidly lose their surface receptors for tumor necrosis factor (TNF) after exposure to various stimuli in vitro. To assess the effect of endotoxin on cellular TNF receptors in humans in vivo, binding of biotinylated TNF to circulating monocytes and granulocytes was determined by fluorescence-activated cell sorter analysis in six healthy subjects after intravenous injection of endotoxin (lot EC-5, 20 U/kg). Endotoxin administration was associated with a transient decrease in monocyte TNF receptors, reaching a nadir after 2 hours (P < .0001), and a more sustained decrease in granulocyte TNF receptors (P < .001). Although the decrease in cellular TNF receptors coincided with increases in soluble TNF receptors types I and II, no correlations were observed between trough monocyte or granulocyte TNF receptors and peak plasma concentrations of soluble TNF receptors. Stimulation of human whole blood with endotoxin resulted in reduced expression of both type I and type II TNF receptors on monocytes and granulocytes. Endotoxin induces downmodulation of monocyte and granulocyte TNF surface receptors in humans in vivo, which may represent a mechanism to reduce excessive activity of TNF during systemic infection.

[1]  S. Deventer,et al.  Effect of postponed treatment with an anti‐tumour necrosis factor (TNF) F(ab')2 fragment on endotoxin‐induced cytokine and neutrophil responses in chimpanzees , 1995, Clinical and experimental immunology.

[2]  M. Feldmann,et al.  Two inhibitors of pro‐inflammatory cytokine release, interleukin‐10 and interleukin‐4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes , 1994, European journal of immunology.

[3]  W. Buurman,et al.  Lipopolysaccharide LPS-mediated soluble TNF receptor release and TNF receptor expression by monocytes. Role of CD14, LPS binding protein, and bactericidal/permeability-increasing protein. , 1994, Journal of immunology.

[4]  W. Buurman,et al.  Slow release of soluble TNF receptors by monocytes in vitro. , 1994, Journal of immunology.

[5]  S. Calvano,et al.  A human tumor necrosis factor (TNF) alpha mutant that binds exclusively to the p55 TNF receptor produces toxicity in the baboon , 1994, The Journal of experimental medicine.

[6]  B. Aggarwal,et al.  TNF induces internalization of the p60 receptor and shedding of the p80 receptor. , 1994, Journal of immunology.

[7]  G F Babcock,et al.  Alterations of neutrophil responses to tumor necrosis factor alpha and interleukin-8 following human endotoxemia , 1994, Infection and immunity.

[8]  P. Barie,et al.  Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients. , 1994, Journal of the American College of Surgeons.

[9]  F. Porteu,et al.  Tumor necrosis factor induces a selective shedding of its p75 receptor from human neutrophils. , 1994, The Journal of biological chemistry.

[10]  T. van der Poll,et al.  Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. , 1994, Blood.

[11]  P. Roux‐Lombard,et al.  Membrane expression and shedding of tumour necrosis factor receptors during activation of human blood monocytes: regulation by desferrioxamine. , 1993, Immunology.

[12]  T. van der Poll,et al.  Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. , 1993, The Journal of infectious diseases.

[13]  C. Natanson,et al.  Endotoxin in Septic Shock , 1993, Anesthesia and analgesia.

[14]  G. D. Martich,et al.  Response of man to endotoxin. , 1993, Immunobiology.

[15]  M. Brockhaus,et al.  Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. , 1992, The Journal of clinical investigation.

[16]  L. Moldawer,et al.  Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[17]  P. Suter,et al.  Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. The J5 Study Group. , 1992, Immunology.

[18]  D. Wallach,et al.  Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors , 1992, The Journal of experimental medicine.

[19]  H. Büller,et al.  Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways , 1990 .

[20]  C. Nathan,et al.  Shedding of tumor necrosis factor receptors by activated human neutrophils , 1990, The Journal of experimental medicine.

[21]  A C Allison,et al.  The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. , 1990, The Journal of clinical investigation.

[22]  H. Schoenfeld,et al.  Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Chang,et al.  Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). , 1990, Circulatory shock.

[24]  K. Tracey,et al.  Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia , 1989, The Journal of experimental medicine.

[25]  C. Nathan,et al.  Macrophages rapidly internalize their tumor necrosis factor receptors in response to bacterial lipopolysaccharide. , 1989, The Journal of biological chemistry.

[26]  Kevin J. Tracey,et al.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.

[27]  S. Lowry,et al.  Endogenous Mechanisms Regulating TNF and IL-1 during Sepsis , 1995 .

[28]  L. Tartaglia,et al.  Two TNF receptors. , 1992, Immunology today.

[29]  H. Holtmann,et al.  Soluble and cell surface receptors for tumor necrosis factor. , 1991, Agents and actions. Supplements.

[30]  L. Moldawer,et al.  Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor a in vitro and in vivo , 2022 .